Exercise, Medicare, and the $11 Billion Question

The Surprising Facts About Exercise: It's Not Weight Loss

Mandsager K et al. JAMA Netw Open. 2018 · Weeldreyer NR et al. Br J Sports Med. 2025 · Duncan GE et al. Diabetes Care. 2003 · Johnson NA et al. Hepatology. 2009 · Edwards JJ et al. Br J Sports Med. 2023 · Noetel M et al. BMJ. 2024

Let me say the quiet part first. Exercise is a poor weight-loss tool. In trial after trial, adding exercise without changing food moves the scale by a couple of kilograms at most, and patients feel cheated when they have done the work and the number barely moved. I hear it every week. So here is the reframe I give them, built on studies that deliberately held body weight flat so you can see what training does on its own.

Fitness outranks thinness. In 122,007 adults who did treadmill testing at the Cleveland Clinic, the most fit had 80% lower all-cause mortality than the least fit, and low fitness carried more risk than smoking, diabetes, or high blood pressure in that same group. A 2025 meta-analysis of nearly 400,000 adults found that people with obesity who were fit had no significant excess mortality compared with fit normal-weight adults, while unfit people at any BMI carried two to three times the risk. That includes unfit people at a normal weight. Fitness is not a stand-in for thinness. It is its own risk factor, and it is the one you can change in twelve weeks.

Metabolism changes without weight loss. Six months of walking with no change in weight, BMI, or waist raised insulin sensitivity by roughly 74%. Four weeks of cycling cut liver fat 21% with body weight unchanged. In a network meta-analysis of 270 blood pressure trials, isometric exercise (think wall sits) lowered blood pressure 8/4 mmHg, the top-ranked modality, ahead of aerobic training. Twelve weeks of training cut sleep apnea severity by about a quarter without significant weight loss. And for depression, walking or jogging outperformed SSRIs in a BMJ network meta-analysis, with the caveat that a 2026 Cochrane update found a smaller effect in the best-designed trials. The direction is solid. The size is still being argued.

The catch, and the prescription. Exercise behaves like a short-acting drug, not a savings account. The insulin-sensitizing effect lasts 24 to 72 hours after a session and returns to baseline after about 15 days of stopping. So frequency beats duration: four short sessions beat one long one, and never let more than 48 hours pass between them. Then add strength, because grip strength predicted death better than systolic blood pressure did in a study of 140,000 adults, and the mortality sweet spot for lifting is only 30 to 60 minutes a week. That is the whole prescription. Move most days, lift twice a week, and track fitness, blood pressure, waist, and sleep instead of the scale. I have collected all of it, with the trials and the doses, on a new Topic Library page, live now: Exercise Changes Six Metabolic Systems. Weight Isn't One of Them.

Medicare covers obesity medication now. Here is the two-minute version.

CMS, Medicare GLP-1 Bridge: Information for Providers · KFF, July 2026 · Full breakdown in the September 10 issue

On July 1, Medicare started paying for obesity medication for the first time since Part D began in 2006. The September 10 issue walked through the whole map, and the response told me the short version needs repeating, because most of the people who qualify still have not heard. It is not a change in the law. It is a demonstration called the GLP-1 Bridge, running July 1, 2026 through December 31, 2027, with a flat $50 per prescription for Foundayo (orforglipron), Wegovy as the injection or the tablet, and Zepbound in the KwikPen only. Zepbound vials and single-dose pens are not included.

Eligibility is a grid, not a label. BMI 35 or higher qualifies on its own. BMI 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension above 140/90 on two or more medications, or chronic kidney disease stage 3a or worse. BMI 27 or higher qualifies with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. You must be 18 or older. Type 2 diabetes, moderate to severe sleep apnea, and noncirrhotic MASH are excluded, because Part D already covers those routes. KFF estimates about 3.8 million beneficiaries fit the grid, roughly 8 percent of Part D enrollees.

The mechanics are where people get stuck. The drug has to be prescribed alongside ongoing lifestyle treatment with structured nutrition and physical activity, and the prescriber attests to it under penalty of perjury. The pharmacy submits the claim first, which triggers a prior authorization back to the prescriber, decided inside 72 hours. There is no appeal, only resubmission. And the $50 does not count toward the Part D deductible or the $2,100 out-of-pocket cap, because the Bridge sits outside Part D. The trap I see most: a BMI of 32 with nothing on the second tier does not qualify, even though the FDA label would allow treatment. Bring the numbers to the visit. BMI, the last blood pressure and how many medications it took, the last A1c, kidney function, and any heart or vascular history.

Notice how this connects to Story One. The attestation requires physical activity as part of treatment, and Medicare has quietly covered that side since 2011 through Intensive Behavioral Therapy for obesity: up to 22 visits a year in primary care, no copay, no deductible, and almost nobody uses it. Ask for both in the same visit. The Arizona Obesity Organization has a clinician guide and a patient guide to the Bridge at ArizonaObesity.org, and if you are on Medicaid rather than Medicare, the state-by-state map is on my coverage page. Arizona still covers nothing for obesity itself. That is a budget vote, not a science question.

Why obesity medications still are not covered, and what it really costs us to wait

The Dr. Francavilla Show, Episode 203: GLP and Obesity Treatment Coverage with Dr. Doug Maready · Released September 21, 2026 · Also on Apple Podcasts and Spotify

This week Dr. Carolynn Francavilla Brown released our conversation on her show, and it asks the question I get from patients, employers, and legislators alike: if obesity is a disease, why are the medications that treat it still left off so many insurance plans? The short answer is that we call the treatment too expensive while never adding up what the disease already costs.

The $11 billion question. Obesity reduces Arizona's economic activity by about $11.1 billion a year, roughly 1.8 percent of the state's GDP, once you count healthcare, lost workdays, workers' compensation, and lost tax revenue. That is not a healthcare bill alone. It is the cost of doing nothing, and it lands on employers, households, and the state budget every year whether anyone writes a check for treatment or not. Colorado, with one of the lowest obesity rates in the country, carries a burden in the billions too.

The real math on coverage. For Arizona Medicaid, the white paper we built through the Arizona Obesity Organization puts year-one coverage for obesity at roughly $7.7 million, rising to about $21 million by year five. Here is the part almost nobody knows: federal price negotiation on the GLP-1s the state already buys for diabetes should save Arizona roughly $8 million a year. Year one is close to budget-neutral. The real challenge is volume, and California's experience, where demand outran the budget and coverage was pulled, is the cautionary tale every state cites.

Why treatment should not need an ROI. We never ask a heart attack or a cancer diagnosis to pay for itself. Obesity keeps getting that test, and it fails it on paper because the costs come up front and the savings arrive years later. On the show I described a 47-year-old patient whose father and brother both had heart attacks at 48. On treatment his triglycerides fell from over 700 to under 100 and his blood pressure normalized. No spreadsheet captures what that is worth, or the pain, mobility, and sleep that come back with it.

If your plan says no. We also talked through the options people do not know they have. Some large employers dropped GLP-1 coverage this year, but a Health Reimbursement Arrangement lets an employer reimburse treatment outside the standard plan, and employees asking HR about it during hiring and benefits season is how that changes. And on taxes: under a longstanding IRS ruling, a weight-loss program to treat diagnosed obesity counts as a medical expense, so it can qualify for HSA or FSA dollars, and some fitness costs can too with a letter of medical necessity from your physician. It is small next to real coverage, but it is real money back. (Check with your tax advisor for your own situation.)

Medicare solved this with one national rule on July 1. Medicaid is still fifty separate decisions, and private insurance is thousands. Treating obesity as a disease on paper is not the same as covering it in practice. Watch the full episode here, and if your employer is weighing its 2027 benefits right now, send it to your HR team.